AIV-001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV-001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. In nonclinical in vivo studies, AIV-001 demonstrated reduced dermal neovascularization and fibroplasia in wound healing models and long residence time in the skin with a single treatment.
AiViva is currently conducting a Phase IIa clinical trial of AIV-001 for the reduction of scar formation. Additionally, AIV-001 is being developed for rosacea and nonmelanoma skin cancers with clinical trials expected to start in 2020.